

Robert Å eparoviÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4312010/publications.pdf>

Version: 2024-02-01

34
papers

606
citations

1307594

7
h-index

713466

21
g-index

34
all docs

34
docs citations

34
times ranked

1140
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Salivary and Serum Ca125 and Routine Blood Tests in Patients with Ovarian Malignancies. Acta Clinica Croatica, 2021, 60, 55-62.	0.2	2
2	Abstract PS6-56: Clinical validity of compartmental analysis of tumor-infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC) - The key is in spatial morphology?. , 2021, , .		0
3	45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial. Annals of Oncology, 2021, 32, S40.	1.2	0
4	Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer. Scientific Reports, 2021, 11, 14395.	3.3	3
5	P-16 How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia. Annals of Oncology, 2021, 32, S101.	1.2	0
6	Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients. Journal of Oncology, 2021, 2021, 1-8.	1.3	4
7	Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. Pathology and Oncology Research, 2021, 27, 1609963.	1.9	2
8	Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice. Cancers, 2021, 13, 5922.	3.7	5
9	Androgen receptors: unclear ubiquitous mechanism or the missing key in the triple-negative breast cancer?. Libri Oncologici, 2020, 48, 20-26.	0.1	0
10	P-177 Overall survival of patients with left-sided metastatic colorectal cancer in real life: Experience from University Hospital for Tumors in Zagreb, Croatia. Annals of Oncology, 2020, 31, S147-S148.	1.2	0
11	110P Prognostic value of compartmental spatial analysis of tumour: Infiltrating lymphocytes in triple-negative breast cancer. Annals of Oncology, 2020, 31, S285.	1.2	0
12	Characteristics and Prognosis of Triple-Negative Breast Cancer Patients: a Croatian Single Institution Retrospective Cohort Study. Acta Clinica Croatica, 2020, 59, 97-108.	0.2	8
13	Phenotype variants of invasive breast cancer differ in associations between the primary tumor size and its Ki-67 value.. Journal of Clinical Oncology, 2020, 38, e12588-e12588.	1.6	0
14	Prognostic value of tumor: Infiltrating lymphocytes and androgen receptors correlation in triple negative breast cancer.. Journal of Clinical Oncology, 2020, 38, e12571-e12571.	1.6	0
15	Oxaliplatin Induced Pulmonary Fibrosis: A Case Report. Acta Clinica Croatica, 2020, 59, 761-764.	0.2	2
16	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. Breast Cancer Research, 2019, 21, 39.	5.0	17
17	Association of tumor cells chemoresistance mechanisms and suboptimal systemic cytotoxic treatment results. Libri Oncologici, 2019, 46, 65-71.	0.1	0
18	Searching for a link between Ki-67 values and HER2 absence in 297 patients with triple-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, e12551-e12551.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Rapid hair depigmentation in patient treated with pazopanib. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224209.	0.5	2
20	Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report. <i>Acta Clinica Croatica</i> , 2018, 57, 577-580.	0.2	2
21	Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial. , 2018, , .		0
22	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 524-524.	1.6	2
23	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
24	GISTs' classifications in predicting aggressive behavior: a single institution experience. <i>Collegium Antropologicum</i> , 2013, 37, 977-84.	0.2	0
25	Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study. <i>Croatian Medical Journal</i> , 2011, 52, 171-177.	0.7	16
26	Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS118-TPS118.	1.6	7
27	0134 CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer. <i>Breast</i> , 2009, 18, S52.	2.2	1
28	1055 Expression of cancer/testis tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO 1 in medullary breast cancer. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 102.	2.2	0
29	Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer. <i>Tumori</i> , 2008, 94, 838-844.	1.1	21
30	Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. <i>Tumori</i> , 2008, 94, 838-44.	1.1	10
31	Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma. <i>Oncology</i> , 2003, 64, 443-449.	1.9	33
32	Parachordoma: A Case Report. <i>Tumori</i> , 2001, 87, 207-210.	1.1	7
33	Prognostic value of prominent DCIS component in the breast-conserving therapy of stage I and II invasive ductal breast cancer. <i>Breast</i> , 1999, 8, 72-76.	2.2	3
34	Unusual features of metastatic atypical carcinoid of the larynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 1998, 255, 318-321.	1.6	8